Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. John’s Wort “Significantly More Effective” Than Prozac, Study Finds

This article was originally published in The Tan Sheet

Executive Summary

St. John's wort is more effective at treating major depressive disorder (MDD) than fluoxetine (Eli Lilly's Prozac), according to a study published in the October Journal of Clinical Psychopharmacology.

You may also be interested in...



Petition To Restrict St. John’s Wort Draws Fire From Industry

Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.

Petition To Restrict St. John’s Wort Draws Fire From Industry

Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.

St. John’s wort vs. Paxil

Dr. Willmar Schwabe Pharmaceuticals' St. John's wort extract WS 5570 is "at least as effective as" GlaxoSmithKline's antidepressant Paxil (paroxetine) "over six weeks of acute treatment in out-patients with moderate or severe unipolar major depression," a Schwabe-funded study finds. The results "support the use of [St. John's wort] as an alternative to standard antidepressants in moderate to severe depression, especially as well-tolerated," A. Szegedi, Charite Universitatsmedizin, Berlin, et al., report in the Feb. 11 British Medical Journal. The study's 251 participants, who ranged in age from 18-70, were randomized to either 900 mg/day WS 5570 or 20 mg paroxetine once daily for six weeks. Response to treatment was measured by change in score on the Hamilton scale from baseline to day 42. The lead author has received consultancy fees from the firm, and two other study authors are employees of Schwabe...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel